Dissecting serotype-specific contributions to live oral cholera vaccine efficacy
Abstract
The O1 serogroup of Vibrio cholerae causes pandemic cholera and is divided into Ogawa and Inaba serotypes. The O-antigen is V. choleraes immunodominant antigen, and the two serotypes, which differ by the presence or absence of a terminally methylated O-antigen, likely influence development of immunity to cholera and oral cholera vaccines (OCVs). However, there is no consensus regarding the relative immunological potency of each serotype, in part because previous studies relied on genetically heterogenous strains. Here, we engineered matched serotype variants of a live OCV candidate, HaitiV, and used a germ-free mouse model to evaluate the immunogenicity and protective efficacy of each vaccine serotype. By combining vibriocidal antibody quantification with single and mixed strain infection assays, we found that all three HaitiV variants - InabaV, OgawaV, and HikoV (bivalent Inaba/Ogawa) - were immunogenic and protective, suggesting the impact of O1 serotype variation on OCV function may be minimal. The potency of OCVs was found to be challenge strain-dependent, emphasizing the importance of appropriate strain selection for cholera challenge studies. Our findings and experimental approaches will be valuable for guiding the development of live OCVs and oral vaccines for additional pathogens.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Oral immunization with a probiotic cholera vaccine induces broad protective immunity against Vibrio cholerae colonization and disease in mice
B. Sit, T. Zhang, … M. K. Waldor·bioRxiv·Feb 20, 2019
- Transient intestinal colonization by a live-attenuated oral cholera vaccine induces protective immune responses in streptomycin-treated mice
B. Fakoya, B. Sit, M. K. Waldor·bioRxiv·May 19, 2020
- Serotype has a significant impact on the virulence of 7th pandemic Vibrio cholerae O1
S. L. Nordqvist, K. Thorell, … M. Lebens·bioRxiv·Oct 16, 2020
- Vibrio cholerae serotype impacts pathogenicity
Franz G. Zingl, Deborah R. Leitner, … Matthew K. Waldor·Nature CommunicationsPeer-reviewed·Jan 19, 2026
- Non-toxigenic Vibrio cholerae challenge strains for evaluating vaccine efficacy and inferring mechanisms of protection
B. Fakoya, K. Hullahalli, … M. K. Waldor·bioRxiv·Dec 17, 2021
- Therapeutic Equivalence, Immunogenicity, and Safety of Euvichol Oral Cholera Vaccine Formulations Compared with WHO-prequalified Shanchol vaccine in Healthy Children and Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Khalid Mohammed Al-Dhayani, Zaid Ahmad Hasan, … Mohammed Sameer Aleryani·bioRxiv·Sep 24, 2026